Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Drug |
Pharmacologic Class |
Indication |
More Information |
| Hematological Disorders | |||
| Altuviiio (antihemophilic factor [recombinant], Fc-VWF-XTEN fusion protein-ehtl) | Recombinant DNA-derived, Factor VIII concentrate | Routine prophylaxis to reduce the frequency of bleeding episodes; on-demand treatment and control of bleeding episodes; and perioperative management of bleeding in patients with hemophilia A.. | Altuviiio Approved as Once-Weekly Factor VIII Therapy for Hemophilia A |
| Kidney Disease | |||
| Filspari (sparsentan) | Endothelin and angiotensin II receptor antagonist | To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression. | Filspari Granted Accelerated Approval to Reduce Proteinuria in IgA Nephropathy |
| Jesduvroq (daprodustat) | Oral hypoxia-inducible factor prolyl hydroxylase inhibitor | Treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least 4 months. | Jesduvroq Approved for Anemia of CKD in Patients on Dialysis |
| Metabolic Disorders | |||
| Lamzede (velmanase alfa-tycv) | Recombinant form of human lysosomal alpha-mannosidase | Treatment of noncentral nervous system manifestations of alpha-mannosidosis. | Lamzede Approved for Noncentral Nervous System Manifestations of Alpha-Mannosidosis |
| Musculoskeletal Disorder | |||
| Kevzara (sarilumab) | Interleukin-6 receptor antagonist | Treatment of adults with polymyalgia rheumatica who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. | Kevzara Approved for Polymyalgia Rheumatica |
| Skyclarys (omaveloxolone) | Activates the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway | Treatment of Friedreich ataxia in patients 16 years of age and older. | Skyclarys Approved for Friedreich Ataxia |
| Oncology | |||
| Trodelvy (sacituzumab govitecan-hziy) | Trop-2 directed antibody and topoisomerase inhibitor conjugate. | For the treatment of adults with unresectable locally advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer who have received endocrine-based therapy and at least 2 additional systemic therapies in the metastatic setting. | Trodelvy Drug Monograph |
| Ophthalmic Disorders | |||
| Eylea (aflibercept) | Vascular endothelial growth factor inhibitor | Treatment of preterm infants with retinopathy of prematurity. | Eylea Drug Monograph |
| Syfovre (pegcetacoplan injection) | Complement inhibitor | Treatment of geographic atrophy secondary to age-related macular degeneration. | Syfovre Drug Monograph |
Please login or register first to view this content.
